Joseph P. Hagan - Jan 12, 2022 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
President and CEO, Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Jan 12, 2022
Transactions value $
$21,520
Form type
4
Date filed
1/26/2022, 03:13 PM
Previous filing
Jan 4, 2022
Next filing
May 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Purchase $21.5K +100K +31.55% $0.22 417K Jan 26, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +1.6M $0.00 1.6M Jan 12, 2022 Common Stock 1.6M $0.26 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.